NetworkNewsBreaks – Trovagene, Inc.’s (NASDAQ: TROV) PCM-075 Obtains Orphan Drug Designation from FDA to Treat AML
Trovagene (NASDAQ: TROV) this morning said that on September 28 the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML). The company is initiating a phase 1b/2 open-label trial to evaluate the safety and anti-leukemic activity of PCM-075 in combination with standard-of-care in patients with AML. The study will take place at 10 research sites across the U.S. "We see the FDA's granting of orphan drug designation for PCM-075 as underscoring the medical need for new therapies for patients with AML and an important step forward…







